Sponsors (2)
The bill strengthens U.S. drug supply resilience and emergency readiness by creating a federally backed six‑month reserve and supporting domestic production, but does so at the cost of taxpayer funding and higher compliance/production burdens that could raise prices and reduce supplier competition.
Patients with chronic conditions and hospitals will face fewer drug shortages because the bill establishes and maintains a six‑month reserve of critical APIs and finished drugs with ongoing replenishment.
Hospitals, patients, and public health systems will have stronger emergency readiness because the Secretary can direct production, transfers, and allocation of reserves during public health emergencies, natural disasters, or CBRN events.
Domestic manufacturers, hospitals, and local governments could see increased U.S. drug manufacturing capacity and supply‑chain resilience due to procurement preferences and support for construction/renovation of U.S./OECD facilities.
Patients—especially those with chronic conditions—could face higher drug prices if manufacturers pass on increased production, storage, and compliance costs from requirements to hold six‑month stocks, maintain domestic/OECD facilities, and meet surge/quality commitments.
Taxpayers will likely bear higher costs because federal funding and potential subsidies support manufacturing, storage, and facility construction (the bill authorizes $500M and contract support).
Preference for domestic or OECD sourcing may reduce participation by lower‑cost foreign suppliers, decreasing competition and potentially raising procurement costs or slowing supply restoration, which could hurt affordability and access.
Based on analysis of 2 sections of legislative text.
Introduced June 12, 2025 by Angela Craig · Last progress June 12, 2025
Requires the HHS Secretary to set up a rolling reserve program that contracts with drug manufacturers and other eligible entities to keep a continuous, replenished supply of critical drugs and their active pharmaceutical ingredients (APIs) that have vulnerable supply chains. Contracted entities must hold a domestic or approved foreign establishment-based reserve—generally a six-month supply—produce on demand, allow transfers of API to other manufacturers during emergencies, and meet quality, capacity, and redundancy requirements; $500 million is authorized for FY2026 and HHS must issue guidance within 180 days and report to Congress biennially.